- Home
- MERC vs PVLA Comparison
MERC vs PVLA Comparison
Compare MERC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MERC
- PVLA
- Stock Information
- Founded
- MERC 1968
- PVLA 2015
- Country
- MERC Canada
- PVLA United States
- Employees
- MERC N/A
- PVLA N/A
- Industry
- MERC Paper
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- MERC Basic Materials
- PVLA Health Care
- Exchange
- MERC Nasdaq
- PVLA Nasdaq
- Market Cap
- MERC 271.5M
- PVLA 249.2M
- IPO Year
- MERC 1987
- PVLA N/A
- Fundamental
- Price
- MERC $3.89
- PVLA $25.92
- Analyst Decision
- MERC Hold
- PVLA Strong Buy
- Analyst Count
- MERC 3
- PVLA 7
- Target Price
- MERC $5.33
- PVLA $46.29
- AVG Volume (30 Days)
- MERC 434.8K
- PVLA 129.2K
- Earning Date
- MERC 07-31-2025
- PVLA 08-15-2025
- Dividend Yield
- MERC 7.75%
- PVLA N/A
- EPS Growth
- MERC N/A
- PVLA N/A
- EPS
- MERC N/A
- PVLA N/A
- Revenue
- MERC $1,996,904,000.00
- PVLA N/A
- Revenue This Year
- MERC $2.43
- PVLA N/A
- Revenue Next Year
- MERC $6.12
- PVLA N/A
- P/E Ratio
- MERC N/A
- PVLA N/A
- Revenue Growth
- MERC N/A
- PVLA N/A
- 52 Week Low
- MERC $3.20
- PVLA $11.17
- 52 Week High
- MERC $8.57
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- MERC 58.53
- PVLA N/A
- Support Level
- MERC $3.52
- PVLA N/A
- Resistance Level
- MERC $4.04
- PVLA N/A
- Average True Range (ATR)
- MERC 0.16
- PVLA 0.00
- MACD
- MERC 0.06
- PVLA 0.00
- Stochastic Oscillator
- MERC 76.92
- PVLA 0.00
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.